| Literature DB >> 32730676 |
Riccardo Montis1, Roger J Davey1, Sarah E Wright1, Grahame R Woollam2, Aurora J Cruz-Cabeza1.
Abstract
We exploit the possible link between structural surface roughness and difficulty of crystallisation. Polymorphs with smooth surfaces may nucleate and crystallise more readily than polymorphs with rough surfaces. The concept is applied to crystal structure prediction landscapes and reveals a promising complementary way of ranking putative crystal structures.Entities:
Keywords: computational chemistry; crystal structure prediction; crystallization; polymorphism; surface rugosity
Year: 2020 PMID: 32730676 PMCID: PMC7693212 DOI: 10.1002/anie.202006939
Source DB: PubMed Journal: Angew Chem Int Ed Engl ISSN: 1433-7851 Impact factor: 15.336
Figure 1Distribution of the maximum difference in normalised crystal rugosity for 2559 polymorphic families (5611 crystal structures) in the CSD.
Average normalised crystal rugosities for polymorphic systems with a form hard to produce and a more common form that is easier to crystallise.
|
|
Easy |
Hard |
| ||
|---|---|---|---|---|---|
|
|
form |
|
form |
|
|
|
rotigotine[3][b] |
I |
−0.402 |
II[c] |
−0.372 |
−0.030 |
|
dapsone |
III |
−0.109 |
V[c] |
−0.106 |
−0.003 |
|
|
α |
−0.061 |
β[d] |
−0.091 |
0.030 |
|
aspirin[ |
I[c] |
−0.070 |
II |
−0.121 |
0.051 |
|
curcumin[20][b] |
I[c] |
−0.233 |
II |
−0.288 |
0.055 |
|
axitinib[21][b] |
XXV |
−0.115 |
XLI[c,e] |
−0.170 |
0.055 |
|
5‐Br‐aspirin[ |
I[c] |
−0.061 |
II |
−0.117 |
0.056 |
|
paracetamol |
I[c] |
−0.153 |
II |
−0.216 |
0.063 |
|
carbamazepine |
III[c] |
−0.125 |
V |
−0.193 |
0.068 |
|
theophylline |
II |
−0.025 |
IV[c] |
−0.161 |
0.136 |
|
ritonavir[27][b] |
I |
−0.114 |
II[c] |
−0.265 |
0.151 |
[a] . [b] Conformational polymorphs. [c] Thermodynamically stable form under ambient conditions. [d] Thermodynamically stable at low temperature. [e] Formed by conversion from a solvate.
Figure 2Illustration of the differences in rugosity between the most dominant face of form II (left) and form IV (right) of theophylline.
Figure 3CSP landscapes: a) diflunisal and b) compound X. Experimental structures are circled in red.